5 results on '"Philip H. Li"'
Search Results
2. Hong Kong–Macau Severe Hives and Angioedema Referral Pathway
- Author
-
Philip H. Li, Elaine Y. L. Au, Si-Leong Cheong, Ling Chung, Ka I. Fan, Marco H. K. Ho, Agnes S. Y. Leung, Martin M. H. Chung, Jane C. Y. Wong, and Ricardo Coelho
- Subjects
angioedema ,hereditary ,hives ,Hong Kong ,Macau ,referral ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundUrticaria (defined as the presence of hives, angioedema, or both) can be caused by a variety of etiologies ranging from more common conditions such as chronic spontaneous urticaria (CSU) to rarer conditions such as hereditary angioedema (HAE). Specialist referral may be necessary in cases of severe urticaria or HAE, but access to specialist services remains limited in certain regions, such as the Greater Bay Area (GBA) of China. To address this, the Hong Kong–Macau Severe Hives and Angioedema Referral Pathway (SHARP) was initiated by the Hong Kong Institute of Allergy and Macau Society of Dermatology to promote multidisciplinary collaboration and regional exchange of expertise in the diagnosis and management of severe urticaria.MethodsA nominated task force of dermatologists and immunologists who manage patients with severe urticaria formulated the consensus statements (CS) using the Delphi method. The consensus was defined a priori as an agreement of ≥80%.ResultsA total of 24 CS were formulated, including four statements on classifications and definitions, seven statements on diagnosis, and 13 statements on management and referral. The definitions for acute/chronic urticaria and severe CSU were stated. Unnecessary investigations and inappropriate medications were discouraged. The characteristics and recommended approach to suspected bradykinergic angioedema were specified. Stepwise treatment options using second-generation antihistamines, omalizumab, or cyclosporin for patients with CSU were addressed, and the importance of access to HAE-specific medications was emphasized. Furthermore, an integrated referral pathway for patients with severe hives and angioedema was constructed.ConclusionThe SHARP provides guidance for the management and specialist referral of patients with severe hives and angioedema in Hong Kong and Macau.
- Published
- 2023
- Full Text
- View/download PDF
3. Differences in beta-lactam and penicillin allergy: Beyond the West and focusing on Asia-Pacific
- Author
-
Hugo W.F. Mak, Maegan H.Y. Yeung, Jane C.Y. Wong, Valerie Chiang, and Philip H. Li
- Subjects
penicillin ,allergy ,Asia-Pacific ,West ,beta-lactam ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Beta-lactam (BL) antibiotic “allergy” labels are common, but often overdiagnosed. Although much research has been focused on the BL allergy and the delabelling process in the West, studies from other parts of the world remain sparse. This review outlines the contrasting global epidemiology, shifting clinical practices and disparities of BL allergy in the Asia-Pacific region compared with the West. Innovative strategies to overcome barriers in BL allergy workup are discussed and potential directions for future research and service development are also proposed.
- Published
- 2022
- Full Text
- View/download PDF
4. Hong Kong Drug Allergy Delabelling Initiative (HK-DADI) consensus statements for penicillin allergy testing by nonallergists
- Author
-
Philip H. Li, Jane C. Y. Wong, Jacky M. C. Chan, Thomas S. H. Chik, M. Y. Chu, Grace C. H. Ho, W. S. Leung, Timothy C. M. Li, Y. Y. Ng, Rocky Shum, Winnie W. Y. Sin, Eugene Y. K. Tso, Alan K. L. Wu, and Elaine Y. L. Au
- Subjects
allergy ,consensus ,Hong Kong ,penicillin ,nonallergist ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionPenicillin allergy testing has been traditionally performed by allergists, but there remains a huge deficit of specialists. A multidisciplinary effort with nonallergists would be invaluable to overcome the magnitude of penicillin allergy labels via the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI). These consensus statements (CSs) offer recommendations and guidance to enable nonallergists to screen for low-risk (LR) patients and perform penicillin allergy testing.MethodsCSs were formulated by the HK-DADI Group using the Delphi method. An agreement was defined as greater than or equal to 80% consensus.ResultsA total of 26 CSs reached consensus after multiple rounds of Delphi. CSs were categorized into risk assessment, skin testing, drug provocation testing (DPT), and post-testing management. For risk assessment, the essentials of allergy history and exclusion criteria were detailed. Patients with only LR features can proceed with testing by nonallergists. Skin tests should be performed prior to DPT. Details regarding the timing, preparation, and interpretation of skin tests were elaborated. DPT remains the gold standard to diagnose genuine allergy or tolerance and should be performed when there is a low pretest probability following negative skin testing. Details of DPT preparations, dosing protocols, and interpretation were elaborated. For post-testing management, inaccurate allergy labels should be delabeled following negative DPT with proper patient counseling.ConclusionCSs support penicillin allergy testing by nonallergists in Hong Kong. LR cases can be managed by nonallergists at Spoke Clinics, with training and support of an allergist-led Hub.
- Published
- 2022
- Full Text
- View/download PDF
5. Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong
- Author
-
Valerie Chiang, Agnes S. Y. Leung, Elaine Y. L. Au, Marco H. K. Ho, Tak Hong Lee, Adrian Y. Y. Wu, Gary W. K. Wong, and Philip H. Li
- Subjects
COVID19 ,allergy ,vaccine ,safety ,consensus ,Hong Kong ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: Mass coronavirus disease 2019 (COVID-19) vaccination to achieve herd immunity is an effective means to mitigate the current COVID-19 pandemic. Reports of COVID-19 vaccine-associated allergic reactions and lack of clear local guidance are contributing factors leading to a low vaccine acceptance rate in the community. A task force of experts from the Hong Kong Institute of Allergy (HKIA) has been formed to address current needs.Objective: To formulate a set of consensus statements (CS) on COVID-19 vaccine allergy safety (VAS) in Hong Kong.Methods: A nominated task force of experts managing patients with drug and vaccine allergies in Hong Kong formulated the CS by the Delphi method. An agreement was a priori defined as ≥80% consensus.Results: A total of 11 statements met the criteria for consensus with good overall agreement among task force members, including seven statements on pre-vaccination recommendations and four statements on vaccination and post-vaccination guidance. Individuals with a history of suspected allergic reaction to prior COVID-19 vaccination should not receive further COVID-19 vaccination, and other groups at risk of COVID-19 vaccine-associated allergic reactions have been identified. The importance of pre-vaccination and post-vaccination assessment by frontline healthcare workers and evaluation by allergists are highlighted.Conclusion: The CS provides pragmatic and timely guidance for local frontline healthcare providers on decisions regarding COVID-19 VAS.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.